Karmanos Cancer Institute receives renewal of National Cancer Institute (NCI) Core Grant
DETROIT, Oct. 13, 2020 /PRNewswire/ -- The Barbara Ann Karmanos Cancer Institute is pleased to announce that its National Cancer Institute (NCI) Core Grant has been renewed. This renewal extends Karmanos' prestigious NCI designation through 2025. Karmanos is among 51 centers nationwide to receive this designation.
NCI-designated cancer centers are characterized by scientific excellence and the capability to integrate a diversity of research approaches to focus on the problem of cancer. They play a vital role in advancing towards the goal of reducing morbidity and mortality from cancer.
"This designation reaffirms what we see at Karmanos every day: that our researchers and clinical staff members are doing outstanding work in their fields," said Gerold Bepler, M.D., Ph.D., president and CEO of the Barbara Ann Karmanos Cancer Institute. "Our NCI designation sets us apart in the fields of cancer research and treatment by showing our patients, colleagues and peers that we are committed to creating a world free of cancer. With this achievement, we are empowered to press forward in the fight against cancer."
To secure grant renewal, Karmanos submitted a 2,000-page application and underwent a site visit by a panel of experts from across the country. The 2020 visit took place virtually for the first time in history, due to the COVID-19 pandemic. This visit resulted in a detailed report including a score sheet. We are proud to report the work of Karmanos' Office of Cancer Health Equity and Community Engagement (OCHECE), which conducts community-based behavioral research, achieved a perfect score of "exceptional". Overall, Karmanos exceeded its standing from 2015 – a result that validates the hard work and dedication of the Karmanos team.
The National Cancer Institute (NCI) first designated the Barbara Ann Karmanos Cancer Institute as a comprehensive cancer center in 1978, when the Institute was called the Meyer L. Prentis Comprehensive Cancer Center of Metropolitan Detroit. It was the first center in Michigan to receive the NCI designation and remains one of only two in Michigan with this title.
To be designated as a comprehensive cancer center by the NCI, a center must:
Karmanos has met these criteria and is pleased to share highlights from our list of accomplishments. In the past five years:
"The renewal of the Core Grant by the National Cancer Institute reinforces Karmanos Cancer Institute's status as one of the best cancer treatment and research operations in the mid-west and the largest in the state of Michigan. This renewal is the result of the hard work and dedication of our clinicians and researchers and enables us to provide bench-to-bedside medicine to our patients," said Philip A. Incarnati, president and CEO of McLaren Health Care. "We are grateful for the renewal of this NCI designation, as it allows us to provide critical resources and develop life-saving cancer treatments in the communities we serve. We can only imagine the continued advances in treatment protocols that will come from this achievement. No doubt, many lives will be saved."
ABOUT THE BARBARA ANN KARMANOS CANCER INSTITUTE
View original content to download multimedia:http://www.prnewswire.com/news-releases/karmanos-cancer-institute-receives-renewal-of-national-cancer-institute-nci-core-grant-301151361.html
SOURCE Karmanos Cancer Institute